hypothyroidism slow acting thyroid slow acting thyroid
Conditions
Interventions
None listed
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Hypothyroid patients - Ability to provide informed consent; - Ability to speak and understand Dutch or English - Intake of a stable dose of levothyroxine, meaning the dosage of levothyroxine must not be changed during the appointment at the outpatient clinic - Diagnosis of one of these forms of hypothyroidism O Patients with primary hypothyroidism: euthyroid based on TSH according to physician O Patients with hypothyroidism after a total thyroidectomy due to thyroid carcinoma (therefore athyroid): on target TSH according to physician (target TSH depending on stage/severity of carcinoma) O Patients using L-T4 due to therapy of Graves* disease: euthyroid based on TSH according to physician (TSH cannot be suppressed, namely TSH within reference interval of 0,5-5,0 mU/L) O Patients with central hypothyroidism: euthyroid based on fT4 according to physician (common is fT4 in the upper limit, reference interval is 12-22 pmol/L) Healthy controls - Ability to provide informed consent; - Ability to speak and understand Dutch or English - Consider themselves healthy
Exclusion criteria
Exclusion criteria: Hypothyroid patients - Not euthyroid according to physician - Pregnant - Patients using L-T4 due to the treatment of Graves* disease: if TSH is still suppressed - Any of the following medication o Iodide o Liothyronine (Cytomel) o Oral anticonceptiva o Active treatment of malignancy (except DTC) Healthy controls - Pregnancy - Any of the following medication o Thyroid medication (a.o. levothyroxine, thiamazol, PTU) o Lithium o Amiodarone o Propranolol o Iodide o Glucocorticoids o Oral contraceptives o Heparin o Growth hormone o Active treatment of malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| fT3, fT3/fT4 ratio and fT4 and TSH concentrations. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Laboratory tests: rT3, TT4, TT3, SHBG, acylcarnitine profile, tyrosine, phenylalanine, serine and DIO1/2/3 polymorphisms - Questionnaire: ThyPRO-39 | — |
Countries
Netherlands
Contacts
Public ContactK.M. Latupeirissa
Amsterdam UMC
Outcome results
None listed